Re­searchers shut­ter 2 Covid-19 stud­ies as mon­i­tors flag Eli Lil­ly an­ti­bod­ies as a flop for pneu­mo­nia, hos­pi­tal­ized pa­tients — but EUA hunt con­tin­ues

Two weeks af­ter the safe­ty da­ta mon­i­tor­ing group ad­vised re­searchers to hit the hold but­ton on a clin­i­cal tri­al of Eli Lil­ly’s an­ti­body bam­lanivimab (LY­CoV55) for pa­tients hos­pi­tal­ized with Covid-19, the tri­al over­seers are back with fresh di­rec­tions to shut­ter the study af­ter los­ing faith that the drug could help this group of pa­tients.

The mon­i­tors con­clud­ed, how­ev­er, that there were no safe­ty is­sues in­volved, which will like­ly en­cour­age con­tin­ued be­lief that Lil­ly can still nail down an emer­gency mar­ket­ing ap­pli­ca­tion for less-sick pa­tients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.